Optimization of DNA vaccination against cutaneous leishmaniasis

Vaccine

Volumn 20, Issue 31-32, 2002, Pages 3702-3708

  Méndez, Susana ^a   Belkaid, Yasmine ^a   Seder, Robert A ^a   Sacks, David ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

CD8+ T cells; DNA vaccines; Leishmania major

Indexed keywords

ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; PROTEIN LACK; PROTEIN LMST11; PROTEIN TSA; UNCLASSIFIED DRUG; INACTIVATED VACCINE; LIVE VACCINE; PARASITE ANTIGEN; PROTOZOAL DNA; PROTOZOON ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL POPULATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; IN VIVO STUDY; INOCULATION; LEISHMANIA MAJOR; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTECTION; SKIN LEISHMANIASIS; T LYMPHOCYTE; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; ISOLATION AND PURIFICATION; LYMPHOCYTE DEPLETION; METHODOLOGY; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DNA, PROTOZOAN; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG ADMINISTRATION ROUTES; IMMUNITY, CELLULAR; IMMUNOLOGIC MEMORY; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; T-LYMPHOCYTE SUBSETS; VACCINATION; VACCINES, ATTENUATED; VACCINES, DNA; VACCINES, INACTIVATED;

EID: 0036827640     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00376-6     Document Type: Article

References (37)

1. Gurunathan S., Wu C.Y., Freidag B.L., Seder R.A. DNA vaccines: a key for inducing long-term cellular immunity. Curr. Opin. Immunol. 12(4):2000;442-447.
2. Thalhamer J., Leitner W., Hammerl P., Brtko J. Designing immune responses with genetic immunization and immunostimulatory DNA sequences (invited review). Endocrinol. Regul. 35(3):2001;143-166.
3. Handman E. Leishmaniasis: current status of vaccine development. Clin. Microbiol. Rev. 14(2):2001;229-243.
4. Mougneau E., Altare F., Wakil A.E.et al. Expression cloning of a protective Leishmania antigen. Science. 268(5210):1995;563-566.
5. Webb J.R., Campos-Neto A., Ovendale P.J.et al. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect. Immun. 66(7):1998;3279-3289.
6. Campos-Neto A., Webb J.R., Greeson K., Coler R.N., Skeiky Y.A., Reed S.G. Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice. Infect. Immun. 70(6):2002;2828-2836.
7. Webb J.R., Kaufmann D., Campos-Neto A., Reed S.G. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. J. Immunol. 157(11):1996;5034-5041.
8. Mendez S., Gurunathan S., Kamhawi S.et al. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J. Immunol. 166(8):2001;5122-5128.
9. Belkaid Y, Mendez S, Lira R, Caler E, Bertholet S, Udey MC, Sacks DL. CD8+ T cells are required for primary immunity in C57Bl/6 mice following low dose, intradermal challenge with Leishmania major. J Immunol, in press.
10. Gurunathan S., Prussin C., Sacks D.L., Seder R.A. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat. Med. 4(12):1998;1409-1415.
11. Gurunathan S., Stobie L., Prussin C.et al. Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells. J. Immunol. 165(2):2000;915-924.
12. Stobie L., Gurunathan S., Prussin C.et al. The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge. Proc. Natl. Acad. Sci. U.S.A. 97(15):2000;8427-8432.
13. Belkaid Y., Kamhawi S., Modi G.et al. Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva pre-exposure on the long-term outcome of Leishmania major infection in the mouse ear dermis. J. Exp. Med. 188(10):1998;1941-1953.
14. Xu D., Liew F.Y. Genetic vaccination against leishmaniasis. Vaccine. 12(16):1994;1534-1536.
15. Walker P.S., Scharton-Kersten T., Rowton E.D.et al. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis. Hum. Gene Ther. 9(13):1998;1899-1907.
16. Sjolander A., Baldwin T.M., Curtis J.M., Handman E.et al. Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis. J. Immunol. 160(8):1998;3949-3957.
17. Skeiky Y.A., Kennedy M., Kaufman D.et al. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J. Immunol. 161(11):1998;6171-6179.
18. Gurunathan S., Sacks D.L., Brown D.R.et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp. Med. 186(7):1997;1137-1147.
19. Piedrafita D., Xu D., Hunter D., Harrison R.A., Liew F.Y. Protective immune responses induced by vaccination with an expression genomic library of Leishmania major. J. Immunol. 163(3):1999;1467-1472.
20. Rafati S., Salmanian A.H., Taheri T., Vafa M., Fasel N. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Vaccine. 19(25/26):2001;3369-3375.
21. Belkaid Y., Mendez S., Lira R., Kadambi N., Milon G., Sacks D. A natural model of Leishmania major infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity. J. Immunol. 165(2):2000;969-977.
22. Maillard I., Launois P., Himmelrich H.et al. Functional plasticity of the LACK-reactive Vbeta4-Valpha8 CD4(+) T cells normally producing the early IL-4 instructing Th2 cell development and susceptibility to Leishmania major in BALB/c mice. Eur. J. Immunol. 31(4):2001;1288-1296.
23. Melby P.C., Yang J., Zhao W., Perez L.E., Cheng J. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect. Immun. 69(8):2001;4719-4725.
24. Campos-Neto A., Porrozzi R., Greeson K.et al. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and non-human primate models of the human disease. Infect. Immun. 69(6):2001;4103-4108.
25. Ulmer J.B., Donnelly J.J., Parker S.E.et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 259(5102):1993;1745-1749.
26. Fynan E.F., Webster R.G., Fuller D.H., Haynes J.R., Santoro J.C., Robinson H.L. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl. Acad. Sci. U.S.A. 90(24):1993;11478-11482.
27. Wang B., Ugen K.E., Srikantan V.et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U.S.A. 90(9):1993;4156-4160.
28. Davis H.L., Michel M.L., Mancini M., Schleef M., Whalen R.G. Direct gene transfer in skeletal muscle: plasmid DNA-based immunization against the hepatitis B virus surface antigen. Vaccine. 12(16):1994;1503-1509.
29. Wang B., Dang K., Agadjanyan M.G.et al. Mucosal immunization with a DNA vaccine induces immune responses against HIV-1 at a mucosal site. Vaccine. 15(8):1997;821-825.
30. Bagarazzi M.L., Boyer J.D., Javadian M.A.et al. Safety and immunogenicity of intramuscular and intravaginal delivery of HIV-1 DNA constructs to infant chimpanzees. J. Med. Primatol. 26(1/2):1997;27-33.
31. Gerloni M., Baliou W.R., Billetta R., Zanetti M. Immunity to Plasmodium falciparum malaria sporozoites by somatic transgene immunization. Nat. Biotechnol. 15(9):1997;876-881.
32. Wolff J.A. Naked DNA transport and expression in mammalian cells. Neuromuscular Disord. 7(5):1997;314-318.
33. Hohlfeld R., Engel A.G. The immunobiology of muscle. Immunol. Today. 15(6):1994;269-274.
34. Casares S., Inaba K., Brumeanu T.D., Steinman R.M., Bona C.A. Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope. J. Exp. Med. 186(9):1997;1481-1486.
35. McShane H., Behboudi S., Goonetilleke N., Brookes R., Hill A.V. Protective immunity against mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8(+)- and CD4(+)-T cell epitopes from antigen 85A. Infect. Immun. 70(3):2002;1623-1626.
36. Gonzalo R.M., del Real G., Rodriguez J.R.et al. A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis. Vaccine. 20(7/8):2002;1226-1231.
37. Gilbert S.C., Schneider J., Hannan C.M.et al. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine. 20(7/8):2002;1039-1045.